Serum amyloid-A in Behçet's disease

Area of Science:

• Rheumatology
• Immunology
• Clinical Medicine

Background:

• Serum amyloid-A (SAA) is an acute phase protein synthesized by the liver.
• SAA has been explored as a disease activity marker in various rheumatologic conditions.
• The role of SAA in Behçet’s disease (BD), a complex inflammatory disorder, remains unclear.

Purpose of the Study:

• To investigate the potential of Serum amyloid-A (SAA) levels as a marker for disease activity in patients diagnosed with Behçet’s disease (BD).

Main Methods:

• This study assessed serum levels of SAA in patients with Behçet's disease.
• Correlation analysis was performed between SAA levels and clinical manifestations of BD.

Main Results:

• Significantly higher SAA serum levels were observed in patients with oral aphthosis (>30 mg/L), neurological impairment (>50 mg/L), and ocular disease (>150 mg/L).
• Increased SAA levels may indicate an elevated thrombotic risk in BD patients with existing or concurrent vascular involvement.

Conclusions:

• Serum amyloid-A (SAA) levels are associated with specific clinical manifestations in Behçet's disease (BD).
• SAA may serve as a valuable biomarker for monitoring disease activity and identifying thrombotic risk in BD.